Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Analysis by Stimulants and Non-stimulants for Pediatrics & Adolescents and Adults from 2024 to 2034
Analysis of XYZ Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Outlook (2024 to 2034)
The global attention deficit hyperactivity disorder (ADHD) therapeutics market size is calculated at US$ 25.05 billion in 2024 and is forecasted to reach a valuation of US$ 45.51 billion by 2034-end. This jump in valuation is because the global market is predicted to increase at 6.2% CAGR over the next ten years (2024 to 2034).
Attention deficit hyperactivity is a neurodevelopmental condition that causes impulsiveness, hyperactivity, and difficulty in staying attentive. The onset of this can often be traced to childhood and this has also been known to persist in people through adulthood as well.
Increasing awareness regarding the symptoms and diagnosis of ADHD is the primary factor that is projected to augment attention deficit hyperactivity disorder therapeutics market development in the future. High focus on mental health, increasing investments in attention deficit hyperactivity disorder research, rising use of adjuvant treatment therapies, and increasing levels of stress among individuals are other factors that are forecasted to benefit ADHD market growth in the long run.
High use of behavioral therapy to treat ADHD could also offer new opportunities for ADHD market players around the world. Attention deficit hyperactivity disorder therapeutics companies are also taking a novel approach by incorporating digital technologies such as virtual reality and gamification.
- In June 2023, Akili, a renowned digital medicine company, announced the launch of its over-the-counter version of the attention-improving game for adults suffering from attention deficit hyperactivity disorder. The company is still waiting to submit the same for an FDA but was able to launch EndeavorOTC due to the policy allowing low-risk digital health tools to be launched without needing a full FDA regulatory review.
On the contrary, the shortage of drugs, the high costs of novel ADHD medications, and increasing awareness regarding side effects of attention deficit hyperactivity disorder therapeutics usage are predicted to be key restraints hampering sales of attention deficit hyperactivity disorder therapeutics across the study period.
| Report Attributes | Details |
|---|---|
| ADHD Therapeutics Market Size (2024E) | US$ 25.05 Billion |
| Projected Market Value (2034F) | US$ 45.51 Billion |
| Global Market Growth Rate (2024 to 2034) | 6.2% CAGR |
| China Market Share (2024E) | 49% |
| East Asia Market Growth Rate (2024 to 2034) | 6.8% CAGR |
| Japan Market Value (2034F) | US$ 666 million |
| Non-stimulant ADHD Therapeutics Demand Growth (2024 to 2034) | 6.8% CAGR |
| Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Will it Be Profitable for Start-ups to Jump into the ADHD Business?
“High Focus on Mental Health Will Create New Market Opportunities”
Mental health awareness has increased substantially in recent years, and this trend is creating new growth scope for attention deficit hyperactivity disorder therapeutics providers as well. New attention deficit hyperactivity disorder therapeutics companies are focusing on taking a novel approach to the treatment of attention deficit hyperactivity disorder and this is where opportunities lie for upcoming ADHD market players.
- In January 2023, Inflow, a United Kingdom-based start-up that focuses on ADHD management through its application, announced that it had raised US$ 11 million in a Series A funding round led by Octopus Ventures along with other investors. The application helps patients manage ADHD through its Cognitive Behavioral Therapy-based support and the company intended to use the raised capital to expand its team and boost product development.
- In May 2021, Healios, a new company focusing on providing online therapy for children, announced that it had raised around US$ 10 million in a funding round led by InHealth Ventures to expand its team and AI and machine learning expertise as well. The company offers a family-focused therapy program for young people affected by autism, ADHD, anxiety, and other mental health concerns.
Gain a crucial understanding of the start-up landscape of the global ADHD therapeutics market from this latest attention deficit hyperactivity disorder therapeutics market study report, compiled by skilled analysts at Fact.MR, a market research and competitive intelligence provider, gives a detailed analysis of factors such as local supply, pricing trends, product standards, safety regulations, and new developments, affecting market growth.
Country-wise Insights
Growing awareness regarding mental health is a common attention deficit hyperactivity disorder therapeutics market trend that is projected to promote demand for ADHD treatment therapies in countries such as the United States, China, Germany, and the United Kingdom through 2034.
Why Should ADHD Therapeutics Suppliers Focus on the United States?
“High Rates of Mental Disorders among Young People”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 16.21 Billion |
| Growth Rate (2024 to 2034) | 5.4% CAGR |
| Projected Value (2034F) | US$ 27.48 Billion |
Prevalence of attention deficit hyperactivity disorder among children and teenagers has been increasing steadily in the United States, which is estimated to boost shipments of attention deficit hyperactivity disorder therapeutics going forward. Another factor favoring market growth is that the country is home to some of the prominent pharmaceutical companies that provide attention deficit hyperactivity disorder therapeutics.
- As per a study done by researchers at the Centers for Disease Control and Prevention (CDC) and the Health Resources and Services Administration, around 6.4 million children of school age have received a diagnosis of ADHD by a healthcare provider.
Rising focus on mental health, increasing healthcare expenditure, growing availability of attention deficit hyperactivity disorder medications for children, and high investments in the R&D of novel therapies for ADHD treatment are other factors that could bolster attention deficit hyperactivity disorder therapeutics sales in the long run. However, surging healthcare costs and drug shortages are predicted to take a chunk out of the United States attention deficit hyperactivity disorder therapeutics market size by the end of 2034.
How Fast Will Sales of ADHD Therapeutics Grow in China?
“Market Benefiting from Growing Awareness of Symptoms of Mental Health Disorders”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 559 Million |
| Growth Rate (2024 to 2034) | 7% CAGR |
| Projected Value (2034F) | US$ 1.1 Billion |
A predominantly popular mental health issue of the West has come knocking on the doors of Asian countries in recent years. Rising awareness regarding the importance of mental health along with the growing willingness of people to test their mental health are projected to bolster sales of ADHD therapeutics in China over the next ten years. The increasing availability of attention deficit hyperactivity disorder drugs in the country and high investments in ADHD research are also estimated to contribute to the increasing East Asia attention deficit hyperactivity disorder therapeutics market share.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Category-wise Insights
Attention deficit hyperactivity disorder therapeutics suppliers are focusing on supplying stimulant ADHD drugs via retail pharmacies to maximize their revenue generation potential over the coming years.
Which Class of ADHD Drugs are Most Widely Prescribed?
“Stimulant ADHD Therapeutics Used More than Non-stimulants”
| Attribute | Stimulants |
|---|---|
| Segment Value (2024E) | US$ 21.51 Billion |
| Growth Rate (2024 to 2034) | 6% CAGR |
| Projected Value (2034F) | US$ 38.7 Billion |
Stimulant drugs have been used to treat attention deficit hyperactivity disorders for quite a while now and their proven efficacy to do so allows them to hold a prominent ADHD therapeutics market share. Adderal, Ritalin, and Dexedrine are some popular stimulants that are used extensively by people suffering from attention deficit hyperactivity disorders. This class of drugs functions by raising the levels of dopamine in the brain and helps ADHD patients increase their focus and concentration.
Where Do Most Sales of ADHD Therapeutics Come From?
“Retail Pharmacies Hold Significant Chunk of Sales Revenue”
| Attribute | Retail Pharmacies |
|---|---|
| Segment Value (2024E) | US$ 11.42 Billion |
| Growth Rate (2024 to 2034) | 6.4% CAGR |
| Projected Value (2034F) | US$ 21.16 Billion |
An increasing number of people suffering from attention deficit hyperactivity disorder are being treated in an outpatient setting owing to the complex nature of this disease. This has resulted in an increased number of prescriptions being written for the treatment of ADHD thereby creating high demand in retail pharmacy settings. Low prices of drugs in a retail pharmacy as compared to other distribution channels are also estimated to favor growth in this segment going forward.
Competitive Landscape
Attention deficit hyperactivity disorder therapeutics manufacturers are focusing on launching more drugs to combat the issue of shortage of drugs in different parts of the world. The patent expiry of novel ADHD therapeutics is opening up the pathway for the launch of generic versions of these medications and supporting the overall attention deficit hyperactivity disorder therapeutics demand outlook as well.
- In September 2023, the shipping of copycat versions of Vyvanse was started by generic drug makers to offset the shortage of ADHD medications in the United States. Vyvanse was an ADHD drug developed by Takeda Pharmaceuticals and its exclusivity expired on 24 August 2023, clearing the path for 11 drug makers to receive FDA approval for manufacturing of the same.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Key Segments of ADHD Therapeutics Market Research
-
By Drug Type :
- Stimulants
- Amphetamine
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Lisdexamfetamine Dimesylate
- Non-stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Clonidine
- Stimulants
-
By Age Group :
- Pediatrics & Adolescents
- Adults
-
By Distribution Channel :
- Specialty Clinics
- Hospital Pharmacies
- Retail Pharmacies
- e-Commerce
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- Middle East & Africa
- FAQs -
How big is the attention deficit hyperactivity disorder therapeutics market?
The global attention deficit hyperactivity disorder (ADHD) therapeutics market is estimated at US$ 25.05 billion in 2024.
What is the projected market valuation for 2034?
Revenue from attention deficit hyperactivity disorder therapeutics is forecasted to reach US$ 45.51 billion by 2034-end.
At what CAGR will ADHD therapeutics sales rise?
The global market is projected to increase at 6.2% CAGR over the next ten years.
Where will attention deficit hyperactivity disorder therapeutics demand soar high?
The market in North America is forecasted to expand at a CAGR of 5.5% from 2024 to 2034.
What is the drug of choice for attention deficit hyperactivity disorder treatment?
Methylphenidate is the most commonly used stimulant for the treatment of ADHD.
Who are the top attention deficit hyperactivity disorder therapeutics manufacturers?
Pfizer Inc., Mallinckrodt Pharmaceuticals, Eli Lily and Company, Purdue Pharma L.P., Novartis AG., and UCB S.A. are leading companies in the market.
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market